FIRST AMENDMENT TO RESEARCH FUNDING AGREEMENT This First Amendment To Research Funding Agreement (the "Amendment"), effective as of March 1, 2001, is entered into by and between Stanislaw R. Burzynski, M.D., PhD. ("Dr. Burzynski") and Burzynski...Research Funding Agreement • May 2nd, 2001 • Burzynski Research Institute Inc • In vitro & in vivo diagnostic substances • Texas
Research Funding AgreementResearch Funding Agreement • May 5th, 2020 • Western Australia
Institution: The Minister for Health is incorporated as the board of [INSERT NAME OF RELEVANT HOSPITAL (S)] under s7 of the Hospitals and Health Services Act 1927 (WA) and has delegated all the powers and duties as such to the Director General of Health
RESEARCH FUNDING AGREEMENTResearch Funding Agreement • December 4th, 2018 • England and Wales
The Funders and the Researchers named above are the Parties to the Agreement. For the avoidance of doubt, any Co-Funders named in Schedule C but not named above and any Co-Researchers named in Schedule D but not named above are not Parties to this Agreement.
RESEARCH FUNDING AGREEMENTResearch Funding Agreement • December 4th, 2018 • England and Wales
Such of Annex 2 (Intellectual Property Rights vested in the Researcher, page 44) or Annex 3 (Intellectual Property Rights retained by AHDB, page
RESEARCH FUNDING AGREEMENT PROJECT TITLE PHA PROJECT NUMBER 20XX-XXX BETWEENResearch Funding Agreement • July 25th, 2023
Poultry Hub Australia (PHA) is located at the University of New England (UNE) in Armidale, NSW While PHA sits within the grounds of UNE, it is a semi-autonomous body with authority to manage its own branding, contracting, financial delegation, and personnel management.
RESEARCH FUNDING AGREEMENTResearch Funding Agreement • August 24th, 2022 • Maine
This Research Funding Agreement (“Agreement”) is entered into as of the date of last signature below (“Effective Date”) between The Jackson Laboratory, a Maine non-profit corporation with a principal place of business at 600 Main Street, Bar Harbor, Maine 04609 (“Jackson”) and (“Institution”).
AMENDMENT NO. 1 to the RESEARCH FUNDING AGREEMENT by and between Affimed Therapeutics AG and The Leukemia & Lymphoma SocietyResearch Funding Agreement • June 27th, 2014 • Affimed Therapeutics B.V. • Pharmaceutical preparations
This Amendment (the “Amendment”) is made as of April 29th, 2014 (the “Amendment Effective Date”), by and between The Leukemia and Lymphoma Society, a New York nonprofit corporation with its principal place of business at 1311 Mamaroneck Avenue, White Plains, New York 10605, United States of America (“LLS”) and Affimed Therapeutics AG, a German limited liability company with its principal place of business at Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (“Affimed”). LLS and Affimed are hereinafter referred to individually as the “Party” and together as the “Parties”.
RESEARCH FUNDING AGREEMENTResearch Funding Agreement • July 7th, 2020
UKZN has submitted a proposal with project title : XXX to XXX (Funder details) and XXX (Funder details) is desirous of having UKZN execute the project.
ContractResearch Funding Agreement • June 14th, 2021
RESEARCH FUNDING AGREEMENT Dated: …………………………………… Parties: (1) The EARTHQUAKE COMMISSIONa Crown entity continuing under the Earthquake Commission Act 1993 (the Commission) (2) ……………………………………………………………………………………………………………… (the Host Institution) Principal Investigator/Supervising Researcher: ………………………………………………………………………… (the Researcher) Project for which funding is granted: “…………………………………………………………………………………………………………………….”(identified as EQC Project No ) (the Project)as described in the attached research proposal dated submitted by the Researcher, and whichforms part of this Research Funding Agreement. Background: • The Commission provides research grants to facilitate research and education about matters relevant tonatural disaster damage, methods of preventing and reducing natural disaster damage and the insurance provided under the Earthquake Commission Act 1993. • The Commission has approved a research grant for the attached research proposal, provisional upon theCommission, the Host
RESEARCH FUNDING AGREEMENT by and between THE SCRIPPS RESEARCH INSTITUTE a California nonprofit public benefit corporation and ChromaPharma, Inc. A Nevada corporation RESEARCH FUNDING AGREEMENTResearch Funding Agreement • August 10th, 2017 • ChromaDex Corp. • Medicinal chemicals & botanical products • California
This Agreement is entered into this 5th day of June, 2017 (the “Effective Date”), by and between The Scripps Research Institute, a California nonprofit public benefit corporation located at 10550 North Torrey Pines Road, La Jolla, California 92037 ("TSRI"), and ChromaPharma, Inc., a Nevada for-profit corporation located at 10005 Muirlands Blvd., Suite G, Irvine, CA 92618 USA ("Sponsor"), with respect to the facts set forth below.
Research Funding Agreement betweenResearch Funding Agreement • May 19th, 2021
THIS RESEARCH FUNDING AGREEMENT (the “Agreement”) is made by and between the Focused Ultrasound Foundation, a 501(c)(3) organization and public charity having its principal place of business at 1230 Cedars Court, Suite 206, Charlottesville, VA 22903 (hereinafter referred to as the “Foundation”) and Fondazione IRCCS Istituto Neurologico C.Besta, , a public Health Care and Research Institution having its principal place of business at Via Giovanni Celoria, 11, Milan, Italy (hereinafter referred to as the “Institution”), and Dr.
RESEARCH FUNDING AGREEMENTResearch Funding Agreement • February 22nd, 2024
The UNIVERSITY OF THE PHILIPPINES, the national university of the Republic of the Philippines, created and operating under Act No. 1870 and Republic Act No. 9500, represented by DR. MICHAEL L. TEE, Professor and Chancellor of the University of the Philippines Manila, representing [name of college] with office address at the 8th Floor, RCB Building, Philippine General Hospital, Manila, from now on referred to as the “UNIVERSITY;”
FIRST AMENDMENT TO RESEARCH FUNDING AGREEMENTResearch Funding Agreement • March 27th, 2003 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
This is the First Amendment to the Research Funding Agreement (the “Agreement”) between Sangamo BioSciences, Inc. (“Sangamo”) and Baxter Healthcare Corporation (“Baxter”), dated January 11, 2000. This First Amendment shall be effective as of November 14, 2002.
RESEARCH FUNDING AGREEMENT by and between Affimed Therapeutics AG and The Leukemia & Lymphoma SocietyResearch Funding Agreement • June 27th, 2014 • Affimed Therapeutics B.V. • Pharmaceutical preparations • New York
This Agreement (the “Agreement”) is made as of August 26th, 2013 (the “Effective Date”), by and between The Leukemia and Lymphoma Society, a New York nonprofit corporation with its principal place of business at 1311 Mamaroneck Avenue, White Plains, New York 10605, United States of America (“LLS”) and Affimed Therapeutics AG, a German limited liability company with its principal place of business at Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (“Affimed”). LLS and Affimed are sometimes hereinafter referred to individually as the “Party” and together as the “Parties”.
RECITALSResearch Funding Agreement • March 14th, 2000 • Sangamo Biosciences Inc • Services-commercial physical & biological research • California
RESEARCH FUNDING AGREEMENTResearch Funding Agreement • October 15th, 2003 • Burzynski Research Institute Inc • In vitro & in vivo diagnostic substances
THIS AGREEMENT effective as of March 1,1997, by and between Stanislaw R. Burzynski, M.D. Ph.D (hereinafter “SRB”) having his principal place of business at 12000 Richmond Avenue, Houston, Texas and the Burzynski Research Institute, Inc., a Delaware Corporation (“BRI”) having its principal place of business at 12000 Richmond Avenue, Houston Texas hereby agree as follows:
RESEARCH FUNDING AGREEMENTResearch Funding Agreement • September 28th, 2023
WHEREAS, COMPANY has agreed to provide funding and support to SPONSOR and its employee, the PRINCIPAL INVESTIGATOR, to conduct a clinical investigation as sponsor-investigator according to a
AMENDED AND RESTATED RESEARCH FUNDING AGREEMENTResearch Funding Agreement • May 22nd, 2023 • Burzynski Research Institute Inc • In vitro & in vivo diagnostic substances
THIS AMENDED AND RESTATED AGREEMENT (the "Agreement”) effective as of May 22, 2023, by and between Stanislaw R. Burzynski, M.D. Ph.D (hereinafter "SRB") with offices at 9432 Katy Freeway, Suite 200, Houston, Texas 77055 and Burzynski Research Institute, Inc. (the "Company"), a Delaware corporation with offices located at 9432 Katy Freeway, Suite 200, Houston, Texas 77055:
RESEARCH FUNDING AGREEMENTResearch Funding Agreement • August 13th, 2023
<NAME OF FUNDING AGENCY>, an agency of the Department of ____, with principal office at <complete address> represented herein by its <position>, <FULL NAME> and hereinafter referred to as <ABBREVIATION OF FUNDING AGENCY>; and
RESEARCH FUNDING AGREEMENTResearch Funding Agreement • February 7th, 2020 • Porto
FUNDAÇÃO BIAL, a public utility entity, with identification No. 503 323 055 and address at à Avenida da Siderurgia Nacional, 4745-457 Coronado (S. Romão e
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. RESEARCH FUNDING AGREEMENT BETWEEN THE RECTOR AND VISITORS OF THE UNIVERSITY OF...Research Funding Agreement • March 8th, 2017 • 22nd Century Group, Inc. • Cigarettes • Virginia
This Research Funding Agreement is entered into as of December 14, 2016 (the “Agreement”), by and between The Rector and Visitors of the University of Virginia, a not-for-profit Virginia educational institution of the Commonwealth of Virginia located at 1001 North Emmet Street, Charlottesville, Virginia 22903 ("University"), and 22nd Century Limited, LLC, a for-profit Delaware limited liability company with its principal place of business at 9530 Main Street, Clarence, New York 14031 ("Sponsor"), for the purposes as hereinafter set forth.
RESEARCH FUNDING AGREEMENTResearch Funding Agreement • November 1st, 2015 • Illinois
NOW, THEREFORE, in consideration of the mutual agreements and covenants contained herein, the receipt and sufficiency of which is hereby acknowledged by the parties, the parties hereby agree as follows:
